159 related articles for article (PubMed ID: 37568010)
1. Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation.
Nørgaard JN; Abildgaard N; Lysén A; Tsykunova G; Vangsted AJ; João C; Remen N; Nielsen LK; Osnes L; Stokke C; Connelly JP; Revheim MR; ; Schjesvold F
Leukemia; 2023 Oct; 37(10):2107-2114. PubMed ID: 37568010
[No Abstract] [Full Text] [Related]
2. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
4. Deepening Responses after Upfront Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction Therapy.
Ebraheem M; Kumar SK; Dispenzieri A; Jevremovic D; Buadi FK; Dingli D; Cook J; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Binder M; Lin Y; Go RS; Siddiqui MA; Kyle RA; Rajkumar SV; Gonsalves WI; Gertz MA
Transplant Cell Ther; 2022 Nov; 28(11):760.e1-760.e5. PubMed ID: 35940527
[TBL] [Abstract][Full Text] [Related]
5. Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.
Bal S; Landau HJ; Shah GL; Scordo M; Dahi P; Lahoud OB; Hassoun H; Hultcrantz M; Korde N; Lendvai N; Lesokhin AM; Mailankody S; Shah UA; Smith E; Devlin SM; Avecilla S; Dogan A; Roshal M; Landgren O; Giralt SA; Chung DJ
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1394-1401. PubMed ID: 32442725
[TBL] [Abstract][Full Text] [Related]
6. [Effect of autologous hematopoietic stem cell transplantation on minimal residual disease in patients with multiple myeloma].
Shen LJ; Zhuansun SY; Ni BW; Zhang MY; Lu SS; Hua YN; Xiao D; Huang HH; Han XF; Zhong L; Zhong H; Wang T; Hou J
Zhonghua Yi Xue Za Zhi; 2022 Sep; 102(36):2861-2867. PubMed ID: 36153871
[No Abstract] [Full Text] [Related]
7. Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Derman BA; Kansagra A; Zonder J; Stefka AT; Grinblatt DL; Anderson LD; Gurbuxani S; Narula S; Rayani S; Major A; Kin A; Jiang K; Karrison T; Jasielec J; Jakubowiak AJ
JAMA Oncol; 2022 Sep; 8(9):1278-1286. PubMed ID: 35862034
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
[TBL] [Abstract][Full Text] [Related]
10. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
11. Favorable Long-Term Outcomes with Autologous Stem Cell Transplantation for High-Risk Multiple Myeloma Patients with a Positive Result On
Cho HJ; Baek DW; Kim JH; Lee J; Chung YK; Jung SH; Song GY; Ahn SY; Ahn JS; Yang DH; Lee JJ; Kim HJ; Hong CM; Jeong SY; Min JJ; Sohn SK; Moon JH
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):113-120. PubMed ID: 34598908
[TBL] [Abstract][Full Text] [Related]
12. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
Tageja N; Korde N; Kazandjian D; Panch S; Manasanch E; Bhutani M; Kwok M; Mailankody S; Yuan C; Stetler-Stevenson M; Leitman SF; Sportes C; Landgren O
Bone Marrow Transplant; 2018 Nov; 53(11):1445-1449. PubMed ID: 29728700
[TBL] [Abstract][Full Text] [Related]
14. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM; Pawlyn C; Cairns DA; Davies FE; Menzies T; Rawstron A; Jones JR; Hockaday A; Henderson R; Cook G; Drayson MT; Jenner MW; Kaiser MF; Gregory WM; Morgan GJ; Jackson GH; Owen RG
J Clin Oncol; 2022 Sep; 40(25):2889-2900. PubMed ID: 35377708
[TBL] [Abstract][Full Text] [Related]
15. [Bortezomib-based induction chemotherapy followed by autologous hematopoietic stem cell transplantation and maintenance in 200 patients with multiple myeloma: long-term follow-up results from single center].
Wu Q; Liu JR; Huang BH; Zou WY; Gu JL; Chen ML; Kuang LF; Zheng D; Xu DR; Zhou ZH; Wang HH; Su C; Tong XZ; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):453-459. PubMed ID: 31340616
[No Abstract] [Full Text] [Related]
16. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.
Keruakous AR; Asch A; Aljumaily R; Zhao D; Yuen C
Transpl Immunol; 2022 Apr; 71():101544. PubMed ID: 35093506
[TBL] [Abstract][Full Text] [Related]
18. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
19. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
